RA
SPRY icon

RiverPark Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

RiverPark Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,703
Closed -$99.5K – 152
2025
Q2 		$99.5K Buy
+5,703
New +$82.3K 0.06% 106

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

RiverPark Advisors's SPRY Position: Q3 2025 in Review

RiverPark Advisors sold out of ARS Pharmaceuticals (SPRY) in Q3 2025, closing a stake of 5,703 shares — an estimated $99.5K sold.

RiverPark Advisors first reported a position in SPRY in Q2 2025 and held it in 1 quarter. The position peaked at $99.5K in Q2 2025. 188 funds tracked by Wall St. Rank hold SPRY as of Q3 2025.

  • RiverPark Advisors reported no remaining ARS Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • RiverPark Advisors sold 5,703 ARS Pharmaceuticals shares in Q3 2025, an estimated $99.5K.
  • RiverPark Advisors first reported a position in ARS Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • RiverPark Advisors's ARS Pharmaceuticals position peaked at $99.5K in Q2 2025.
  • 188 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2025.

Based on RiverPark Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.